Updated KANDLELIT-001 Data Show Durable Responses With Frontline Calderasib Plus Pembrolizumab in KRAS G12C–Mutated NSCLC
Longer follow-up of KANDLELIT-001 supports frontline calderasib plus pembrolizumab in KRAS G12C–mutated metastatic non–small cell lung cancer Eligible patients had KRAS G12C mutations confirmed by histologic or blood-based testing, an ECOG performance status of 0 or 1, and measurable disease...
